COS.L Regulatory News (COS)

27 March 2017

Collagen Solutions Plc

(the "Company" or the "Group")

Issue of Equity and Director/PDMR Shareholding

Issue of Equity

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has allotted, in aggregate, 8,000,000 new ordinary shares in the Company ("Ordinary Shares") to certain vendors of Collbio Limited ("Collbio") in order to satisfy the second tranche of the deferred consideration share provisions in relation to the acquisition, as announced on 10 December 2013. 

Application has been made for the 8,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 30 March 2017. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 324,299,077 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company. 

Director/PDMR Shareholding

The Company announces that, pursuant to the issue of Ordinary Shares in respect of the satisfaction of the initial tranche of deferred consideration for the Collbio acquisition, Mr David Evans, Chairman of the Company and a vendor of Collbio, was issued 2,685,437 new Ordinary Shares at a strike price of 12.5p per Ordinary Share, and Dr Stewart White, Chief Scientific Officer and a vendor of Collbio, was issued 1,553,592 Ordinary Shares at a strike price of 12.5p per Ordinary Share. Following the issue of new Ordinary Shares to Mr Evans and Dr White, Mr Evans' total beneficial holding in the Company has increased to 38,494,554 Ordinary Shares, representing 11.9 per cent. of the issued ordinary share capital of the Company following Admission, and Dr White's total beneficial holding in the Company has increased to 6,571,511 Ordinary Shares, representing 2 per cent. of the issued ordinary share capital of the Company following Admission respectively.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. For additional information, please visit www.collagensolutions.com.